Please login to the form below

Not currently logged in
Email:
Password:

DoH may overturn NICE decision

The Department of Health is making plans to overrule NICE's decision to scrap the availability of certain Alzheimer's disease treatments on the NHS.

The Department of Health is making plans to overrule a decision by the National Institute for Clinical Excellence (NICE) to scrap the availability of certain Alzheimer's disease treatments through the NHS.

Last week, NICE released interim guidance stating that cholinesterase inhibitors used to treat Alzheimer's disease - including Aricept, Exelon and Reminyl -should not be available routinely on the NHS. Despite clearing the drugs for use through the health system in 2001, the guidance claimed that the drugs failed to improve sufferer's quality of life and were not cost-effective.

However, the DoH has said that it will ask NICE to rethink its decision. ìIn view of the public concern over the draft proposals, the government will want to ensure that all aspects have been fully considered,î it stated.

ìIn particular, the DoH will be asking NICE whether the wider social implications of not approving the drugs' use have been fully taken into account, especially the benefits and costs to carers as well as patients.î

Health minister, Stephen Ladyman, has also voiced his concerns on the decision. He told the Observer: ìThey [NICE] have to look at the wider impact of this decision. It may well be that once they have looked at the extra evidence they will come to a different decision.î

His comments were backed by Dr Paul Hooper, managing director of Eisai, which markets Aricept: ìIt is comforting to know that Stephen Ladyman shows a lot more common sense than the NICE appraisal committee that came up with this perverse proposal,î he said.

Although the DoH's plans to intervene were welcomed by Alzheimer's charities, which are planning mass protests outside parliament this week, others remained concerned that NICE's position could be undermined by a u-turn decision.

Professor Alan Maynard, a leading health economist from the University of York, said that if NICE's decision was overruled, it would ìundermine the whole mechanismî and suggest that the body was ìseriously deficientî.

ìThe reality is that if you put money into things that are of no, or very marginal, benefit, you are denying other patients treatments that could provide greater benefits,î he added.

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....